PACAP is often discussed as though it were one peptide with one receptor response. The original isolation work instead describes two molecular forms, and receptor studies add another layer of variation. Recording both the ligand form and receptor construct makes the literature easier to compare without creating separate, repetitive stories for every abbreviation.
Two forms with a shared beginning
Miyata and colleagues’ 1989 isolation paper identified a 38-residue amidated peptide from ovine hypothalamus. In 1990, the group described a second form corresponding to its first 27 residues, also ending in an amide.Miyata and colleagues — Isolation of PACAP-38 (opens in a new tab)Miyata and colleagues — Isolation of PACAP-27 (opens in a new tab)
| Form | Molecular distinction |
|---|---|
| PACAP-38 | A 38-residue chain with its own amidated endpoint |
| PACAP-27 | The shared first 27 residues, amidated at that shorter endpoint |
The shorter form is therefore not simply a lower concentration of the longer form. Its endpoint is at a different residue, and its terminal chemistry belongs to that endpoint.
The form number should survive every stage of a literature summary: search notes, data table, figure caption and conclusion. Dropping it can turn a direct comparison into an apparently inconsistent set of results for one unspecified reagent.
The discovery assay explains the name
PACAP expands to pituitary adenylate cyclase-activating polypeptide. The original study used activity in rat pituitary cells to help identify the peptide; its authors did not claim that this experiment had established its principal physiological role.Miyata and colleagues — Isolation of PACAP-38 (opens in a new tab)
The PACAP-27 paper reported strong stimulation of adenylyl cyclase in the pituitary assay, comparable with PACAP-38 under that comparison. This supplies a defined example of shared activity rather than a guarantee of equal responses everywhere.Miyata and colleagues — Isolation of PACAP-27 (opens in a new tab)
A name derived from an assay can remain useful long after research expands beyond that assay. It should not be read as a complete tissue distribution map, nor as proof that pituitary signalling is the only relevant context.
PAC1 is not always a single construct
Dautzenberg and colleagues’ 1999 study compared three human PAC1 splice variants with different extracellular amino-terminal regions. The receptor constructs had the same third intracellular loop in that comparison.Dautzenberg and colleagues — Human PAC1 splice variants (opens in a new tab)
In stably transfected HEK293 cells, the variants differed in ligand binding and signalling. One shortened variant showed high affinity for VIP as well as the two PACAP forms, while another larger deletion reduced PACAP affinity substantially.Dautzenberg and colleagues — Human PAC1 splice variants (opens in a new tab)
This result means that a blanket claim about PAC1 distinguishing PACAP from VIP can miss the particular receptor variant. It does not mean that all natural tissues express those variants in the same proportions.
When comparing receptor studies, preserve the species, splice-variant designation and construct description. “Human PAC1” may narrow the question without fully defining the experimental receptor.
Keep ligand variation and receptor variation on separate axes
A useful comparison grid has ligand form across one axis and receptor construct down the other. Each filled cell contains the actual measured outcome, such as binding affinity or a cyclic-AMP response, rather than a single general activity score.
An empty cell is missing evidence, not proof of inactivity. This is particularly important when a study characterises one form thoroughly but includes the other only as a limited comparator.
The same discipline helps explain apparent disagreements: two groups may have used the same ligand abbreviation but different PACAP forms, or the same receptor name but different constructs. Those differences should be checked before proposing a biological contradiction.
This molecular account is a guide to reading PACAP experiments. It does not turn receptor pharmacology into a recommendation for human administration or establish that one form has a clinical advantage over the other.
Sources and further detail
- Miyata and colleagues — Isolation of PACAP-38 (opens in a new tab)
Original 1989 abstract read, including ovine origin, amidated 38-residue structure and pituitary-cell assay.
- Miyata and colleagues — Isolation of PACAP-27 (opens in a new tab)
Original 1990 abstract read for the shared first 27 residues, terminal amide and assay-specific comparison.
- Dautzenberg and colleagues — Human PAC1 splice variants (opens in a new tab)
Complete original 1999 abstract read. Amino-terminal deletions, common intracellular loop and transfected-cell model retained.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.